John Kaiser has been appointed CEO of Research Triangle Park, NC-based Evecxia Therapeutics. Kaiser, who has been working with the company since March, was most recently interim CEO of Baltimore-based Cerecor (NASDAQ: [[ticker:CERC]]). His experience also includes positions at Denysias Bioscience, Acadia Pharmaceuticals (NASDAQ: [[ticker:ACAD]]), and Eli Lilly (NYSE: [[ticker:LLY]]). Evecxia, a Duke University spinout, has developed a formulation of 5-hydroxytryptophan and low-dose carbidopa, two drugs used to treat symptoms of Parkinson’s disease. Evecxia says it is developing a slow-release pill version of the drug combination to treat depression in patients who don’t respond adequately to currently available depression drugs.
